Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

16 Jan 2020 01:18 0
23
OncLiveTV Download
0 0

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative breast cancer.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive

Related of "Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer" Videos